ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...4/The-best-approach-to-oligometastatic-NSCLC

Date: 27 Sep 2014
Presenter: Jaroslaw Kuzdzal
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-locally-advanced-non-small-cell-lung-cancer

AimComputed tomography (CT) scan, despite its limitation of imaging sequence, is the standard tool for response assessment following chemo-radiation in locally advanced non-small cell lung cancer (LA-NSCLC).

Date: 27 Sep 2014
Presenter: Soumyajit Roy
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Locally Advanced, Imaging, Diagnosis and Staging

http://oncologypro.esmo.org/Meeting-Resourc...ge-non-small-cell-lung-cancer-NSCLC-patients

AimPreviously, we reported on early weight loss (WL) and muscle weakness during CCRT that could not be attributed to acute radiation esophagitis (ARIE). Thus, we here hypothesized that early WL reflects...

Date: 27 Sep 2014
Presenter: Lizza Hendriks
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-met-negative-expression-ML28941-C-TONG-1306

BackgroundNon-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations show excellent clinical benefit to Erlotinib. Since EGFR wild type constitutes approximately...

Date: 27 Sep 2014
Presenter: Zhang Li
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Non-Small-Cell Lung Cancer, Metastatic, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...d-MPM-with-deregulated-FGF-pathway-signaling

BackgroundFP1039/GSK3052230 (GSK230) is a soluble fusion protein that acts as a ligand trap by sequestering fibroblast growth factors (FGFs) involved in tumor growth.

Date: 27 Sep 2014
Presenter: Pilar Garrido
Resources: Abstract
Topics: Drug Development, Non-Small-Cell Lung Cancer, Locally Advanced, Mesothelioma, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...us-cell-SCC-non-small-cell-lung-cancer-NSCLC

BackgroundIn a phase 3 trial, nab-P/C vs solvent-based paclitaxel + C demonstrated a 68% improvement in ORR (41% vs 24%; P < 0.001) and a trend toward improved overall survival (OS; median 10.7 vs 9.

Date: 27 Sep 2014
Presenter: David Spigel
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...squamous-non-small-cell-lung-cancer-NS-NSCLC

AimThis study was designed to evaluate the response rate of Pem-Cis as preoperative CT in patients with stage IIIAN2 NS NSCLC. The neoadjuvant setting provided the opportunity to obtain tumor tissue...

Date: 27 Sep 2014
Presenter: Ugo Pastorino
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...ciated-antiemetic-prophylaxis-Santarem-Study

AimNausea and vomiting are some of chemotherapy's most disabling side effects. Our main objective was to compare the impact in quality of life (QoL) of different antiemetics for chemotherapy-induced...

Date: 27 Sep 2014
Presenter: Bárbara Parente
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...motherapy-in-Stage-III-NSCLC-a-phase-I-study

AimWe have shown that αvß3 integrins control radioresistance, hypoxia and angiogenesis and that co-expression of FGF-2 and αvß3 integrins in the tumors of patients treated with exclusive radio...

Date: 27 Sep 2014
Presenter: Elizabeth Cohen-Jonathan Moyal
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ed-with-neoadjuvant-CCRT-followed-by-surgery

AimThe aim of this study was to evaluate the clinical implications of DNA methylation of tumor suppressor gene in pathologic complete responders in stage IIIA(N2) NSCLC patients treated with neoadjuvant CCRT followed by surgery.

Date: 27 Sep 2014
Presenter: Jae Hyun Kim
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Translational Research, Surgery and/or Radiotherapy of Cancer